Corbus PharmaceuticalsCRBP
CRBP
About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Employees: 28
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
747% more call options, than puts
Call options by funds: $6.57M | Put options by funds: $776K
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
7% less funds holding
Funds holding: 107 [Q3] → 99 (-8) [Q4]
7.77% less ownership
Funds ownership: 97.69% [Q3] → 89.92% (-7.77%) [Q4]
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
47% less capital invested
Capital invested by funds: $243M [Q3] → $129M (-$114M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$50
569%
upside
Avg. target
$59
694%
upside
High target
$75
904%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 15 / 53 met price target | 569%upside $50 | Buy Reiterated | 12 Mar 2025 |
Jefferies Maury Raycroft 13% 1-year accuracy 1 / 8 met price target | 610%upside $53 | Buy Maintained | 11 Mar 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target | 904%upside $75 | Buy Reiterated | 18 Feb 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 day ago
3 Unconventional Cannabis Stocks to Watch in 2025
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 764.2% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the United States under an open IND.
Negative
Zacks Investment Research
1 month ago
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Negative
Zacks Investment Research
1 month ago
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
1 month ago
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
2 months ago
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
Neutral
GlobeNewsWire
2 months ago
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (“Western study”) of CRB-701 (SYS6002) has been released. The corresponding up-to-date data will be presented as a poster during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The data from 31 patients referred to in the abstract dates to September 2024; the upcoming poster presentation will include data on 38 patients as of December 2024. ASCO GU will be held in San Francisco, CA February 13-15, 2025.
Neutral
GlobeNewsWire
3 months ago
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings.
Neutral
GlobeNewsWire
3 months ago
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings.
Charts implemented using Lightweight Charts™